依折麦布在他汀类药物致肝功能损害急性冠状动脉综合征患者中的应用

The clinical study of Ezetimibe in patients with ACS complicated with statins-induced liver damage

目的:探讨依折麦布在他汀类药物致肝功能损害的急性冠状动脉综合征(ACS)患者中应用的疗效及安全性。方法:连续入选因肝功能损害不耐受他汀类药物的ACS患者92例,停用他汀类药物后随机化分为对照组(46例)和依折麦布组(46例)。比较治疗两周后两组的血脂、肝功能及临床心血管事件。结果:治疗两周后,依折麦布组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平显著低于对照组;两组心血管事件的发生无明显差异。结论:对于因肝功能损害需要暂时中断他汀类药物治疗的ACS患者,可应用依折麦布作为过渡期的调脂治疗。

Objective：To investigate the clinical efficacy and safety of ezetimibe on patients with acute coronary syndrome complicated with liver damage induced by statins. Method： The 92 consecutively enrolled patients with ACS complicated with liver damage were randomly divided into control group （46 cases） and ezetimibe group （46 cases）. The blood lipid, liver function and clinical cardiovascular events were compared between the two groups after 2 weeks. Result：After two weeks of treatment, the levels of total cholesterol（TC） and low density lipoprotein cholesterol （LDL-C） in ezetimibe group （TC） were significantly lower than control group; and there was no significant difference in cardiovascular events between the two groups. Conclusion：For patients with ACS who requiring temporary interruption of statins therapy because of liver function damage, Ezetimibe can be used for lipid- lowering therapy during the transitional period.